Skip to main content
. 2015 Aug 23;2015:403576. doi: 10.1155/2015/403576

Figure 5.

Figure 5

Validation of a prognostic signature conditioning poor outcomes in subsets of ER(−) IDCs and 181 IDCs. Poor clinical outcome in a subset of ER(−) IDCs and a subset of 181 IDCs is determined by 15 probes that are predicted to be regulated by a transcription factor, NR5A2. Panel (a, b) presents the heatmap displaying 15 prognostic relevant probes, which are predicted to show the consensus expression pattern in both the 91A and 181A cohorts. These 15 probes are part of the most relevant transcriptional activities of NR5A2 in a subset of ER(−) IDCs (a) or in the subset of 181 IDCs predominantly containing ER(−) subtype (b). Panel (c, d) demonstrates significant differences in clinical outcomes based on Kaplan-Meier survival curves when comparing subcohorts I (12A)/II (12A) (c) and subcohorts III (18A)/IV (18A) (d). “NT” stands for nontumor component.